Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy

Progress in Drug Research

Volumn 63, Issue , 2005, Pages 93-114

  Ciardiello, Fortunato ^a   De Vita, Ferdinando ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HR3; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PELITINIB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; ESOPHAGUS CANCER; FEVER; FLUSHING; FOLLICULITIS; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

EID: 26044459745     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/3-7643-7414-4_5     Document Type: Review

References (107)

1. Sporn MB, Todaro GJ (1980) Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878-880
2. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 19: 183-232
3. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970
4. Grunwald V, Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867
5. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799
6. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167
7. Yarden Y, Sliwkowski MX (2001) Untantling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137
8. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21
9. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225
10. McClelland RA, Barrow D, Madden T-A et al (2001) Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142: 2776-2788
11. Wosikowski K, Schuuruis D, Kops GJPL, Saceda M, Bates SE (1997) Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 3: 2405-2414
12. Knowlden JM, Hutcheson IR, Jones HE et al (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044
13. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884-2890
14. Mendelsohn J (2000) Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res 6: 747-753
15. Fan Z, Lu Y, Wu X, Mendelsohn J (1994) Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269: 27595-27602
16. Fan Z, Baselga J, Masui H, Mendelsohn J (1992) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637-4642
17. Baselga J, Norton L, Masui H et al (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327-1333
18. Baselga J (2003) Targeting EGFR with MAbs versus TKIs: different mechanisms, similar endpoints. Signal 4: 4-6
19. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311-1318
20. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ (1998) Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4: 2957-2966
21. Wu X, Rubin M, Fan Z et al (1996) Involvement of p27kipl in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12: 1397-1403
22. Peng D, Fan Z, Lu Y, Deblasio T, Scher H, Mendelsohn J (1996) Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces Gl arrest in prostatic cancer cell line DU145. Cancer Res 56: 3666-3669
23. Di Gennaro E, Barbarino M, Bruzzese F et al (2003) Critical role of both p27kip1 and p21cip1/waf1 in the antiproliferative effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195: 139-150
24. Ciardiello F, Damiano V, Bianco R et al (1996) Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 88: 1770-1776
25. Perrotte P, Matsumoto T, Inoue K et al (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257-265
26. Ciardiello F, Bianco R, Damiano V et al (2000) Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747
27. Bruns CJ, Harbison MT, Davis DW et al (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6: 1936-1948
28. Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465
29. Hirata A, Ogawa S, Kometani T et al (2002) ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62: 2554-2560
30. Huang S-M, Li J, Harri PM (2002) Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 1: 507-514
31. Ciardiello F, Caputo R, Bianco R et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063
32. Ciardiello F, Bianco R, Damiano V et al (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909-916
33. Inoue K, Slaton JW, Perrotte P et al (2000) Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6: 4874-4884
34. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C255 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003
35. Milas L, Mason K, Hunter N et al (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701-708
36. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 15: 1935-1940
37. Bianco C, Bianco R, Tortora G et al (2000) Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6: 4343-4350
38. Huang SM, Harari P (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166-2174
39. Sirotnak FM, Zakowsky MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892
40. Williams K, Telfer BA, Stratford IJ, Wedge SR (2002) ZD1839 (Iressa), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86: 1157-1161
41. Xu J-M, Azzariti A, Severino M, Lu B, Colucci G, Paradiso A (2003) Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol 66: 551-563
42. Magne N, Fischel J-L, Tiffon C et al (2003) Molecular mechanisms underluing the interaction between ZD1839 ("Iressa") and cisplatin/5-fluorouracil. Br J Cancer 89: 585-592
43. Bianco C, Tortora G, Bianco R et al (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 ('Iressa'). Clin Cancer Res 8: 3250-3258
44. Huang S, Li J, Harari PM (2002) Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas. Cancer Res 62: 4300-4306
45. She Y, Lee F, Chen J et al (2003) The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 9: 3773-3778
46. Ciardiello F, Caputo R, Bianco R et al (2002) ZD1839 ('Iressa'), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 98: 463-469
47. Normanno N, Campiglio M, De Luca A et al (2001) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65-72
48. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895
49. Anido J, Matar P, Albanell J et al (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283
50. Moasser MM, Basso A, Averbuch SD, Rosen N (2001) The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188
51. Baselga J, Pfister D, Cooper MR et al (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18: 904-914
52. Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen reeptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935
53. Saltz L, Rubin M, Hochster H et al (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20: abstr. 7
54. Saltz L, Meropol NJ, Loeher PJ et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208
55. Lenz HJ, Mayer RJ, Gold PJ et al (2004) Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 23: abstr. 3510
56. Cunningham D, Humblet Y, Siena S et al (2004) A randomized comparison of cetuximab monotherapy and cetuximab plus irinotecan in irino-tecan-refractory metastatic colorectal cancer. N Engl J Med 351; in press
57. Rougier P, Rasoul J-L, Van Laethem J-L et al (2004) Cetuximab (Erbitux) combined with FOLFIRI (irinotecan plus infusional 5-FU and folinic acid given every two weeks) in patients with epidermal growth factor receptor-expressing advanced colorectal cancer. Proc Am Soc Clin Oncol 23: abstr. 3513
58. Tabernero JM, Van Cutsem E, Sastre J et al (2004) An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 23: abstr. 3512
59. Robert F, Ezekiel MP, Spencer SA et al (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234-3243
60. Bonner JA, Giralt J, Harari PM et al (2004) Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 23: abstr. 5507
61. Burtness B, Li Y, Flood W et al (2002) Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGFR) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc Am Soc Clin Oncol 21: abstr. 901
62. Trigo J, Hitt R, Koralewski P et al (2004) Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 23: abstr. 5502
63. Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4: 397-406
64. Ranson M, Hammond LA, Ferry D et al (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20: 2240-2250
65. Herbst RS, Maddox A-M, Rothenberg ML et al (2002) Selective oral epidermal growth factor receptor tyrosine inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815-3828
66. Baselga J, Rischin D, Ranson M et al (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types:. J Clin Oncol 21: 4292-4302
67. Nakagawa K, Tamura T, Negoro S et al (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14: 922-930
68. LoRusso P, Herbst RS, Rischin D et al (2003) Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 9: 2040-2048
69. Johnson DH, Arteaga CL (2003) Gefitinib in recurrent non-small cell lung cancer: an IDEAL trial? J Clin Oncol 21: 2227-2229
70. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 2237-2246
71. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290: 2149-2158
72. R) Tablets. Oncologist 8: 303-306
73. Cappuzzo F, Gregorc V, Rossi E et al (2003) Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21: 2658-2663
74. Pallis AG, Mavroudinis D, Androulakis N et al (2003) ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer 40: 301-307
75. Gridelli C, Maione P, Castaldo V, Rossi A (2003) Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 89: 1827-1829
76. Gelibter A, Ceribelli A, Milella M et al (2003) Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) in non small cell lung cancer. J Exp Clin Cancer Res 22: 481-485
77. Villano JL, Mauer AM, Vokes EE (2003) A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 14: 656-658
78. Cappuzzo F, Ardizzoni A, Soto-Parra H et al (2003) Epidermal growth factor receptor targeted therapy by ZD1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 41: 227-231
79. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
80. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
81. Green MR (2004) Targeting targeted therapy. N Engl J Med 350: 2191-2193
82. Giaccone G, Johnson DH, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cispatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784
83. Herbst R, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794
84. Dancey JE, Freidin B (2003) Targeting epidermal growth factor receptor - are we missing the mark? Lancet 362: 62-64
85. Inoue A, Saijo Y, Maemondo M et al (2003) Severe interstitial pneumonia and Gefitinib. Lancet 361: 137-139
86. Soria J-C, Le Chevalier T (2003) Interstitial lung disease in NSCLC. Signal 4: 2-3
87. Hidalgo M, Siu LL, Nemunaitis J et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279
88. Bulgaru AM, Mani S, Goel S, Perez-Soler R (2003) Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther 3: 269-279
89. Soulieres D, Senzer NN, Vokes EE et al (2001) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 22: 77-85
90. Finkler N, Gordon A, Crozier M et al (2001) Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 20: abstr. 831
91. Perez-Soler R, Chachoua A, Huberman M et al (2001) A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: abstr. 1235
92. Shepherd FA, Pereira J, Ciuleanu TE et al (2004) A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of first line or second line chemotherapy. A National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 23: abstr. 7022
93. Gatzemeier U, Pluzanska A, Szczesna A et al (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotehrapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23: abstr. 7010
94. Herbst RS, Prager D, Hermann R et al (2004) TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23: abstr. 7011
95. Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39: 1348-1354
96. Viloria-Petit A, Crombet T, Jothy S et al (2001) Aquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61: 5090-5101
97. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207
98. Bianco R, Shin I, Ritter C et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822
99. She QB, Salit S, Basso A, Moasser M (2003) Resistance to Gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidinil 3′ kinase/Akt pathway signaling. Clin Cancer Res 9: 4340-4346
100. Ciardiello F, Bianco R, Caputo R et al (2004) Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. Clin Cancer Res 10: 784-793
101. Wu YL, Yang X-N, Gu L-J (2003) The charactetistics of patients with non-small cell lung cancer with complete response treated with ZD1839. Proc Am Soc Clin Oncol 22: abstr. 2770
102. Wong N-S, Lim ST, Lim W-T, Leong S-S, Tan E-H (2003) ZD1839 is more effective in patients with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users. Proc Am Soc Clin Oncol 22: abstr. 2790
103. Shah NT, Miller VA, Kris MG et al (2003) Bronchioalveolar histology and smoking history predict response to gefitinib. Proc Am Soc Clin Oncol 22: abstr. 2524
104. Miller VA, Kris MG, Shah N et al (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103-1109
105. Saltz LB, Kies MS, Abbruzzese JL, Azarnia N, Needle M (2003) The presence and intensity of the Cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 23: abstr. 817
106. Clark GM, Perez-Soler R, Siu L, Gordon A, Santabarbara P (2003) Rash severty is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 22: abstr. 786
107. Arteaga CL, Baselga J (2003) Clinical trial design and endpoints for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 9: 1579-89